Quality Systems – Page 268

Particulate Matter Oos during routine EM trending: FDA/MHRA investigation narrative and batch impact

Understanding OOS Results for Particulate Matter in Environmental Monitoring Trends: A Structured Investigation Particulate matter (PM) unexpectedly flagged as out-of-specification (OOS) during routine environmental monitoring (EM) can cause significant concerns…

Air Entrapment in cream manufacturing: packaging compatibility and stability justification

Investigating Air Entrapment in Cream Manufacturing: Ensuring Packaging Compatibility and Stability In pharmaceutical cream manufacturing, air entrapment can lead to significant quality issues, impacting both packaging compatibility and product stability.…

Aseptic Gowning Deviation during terminal sterilization: risk assessment for patient safety and recall

Aseptic Gowning Deviation during Terminal Sterilization: Assessing Risk and Ensuring Compliance In the highly regulated world of pharmaceutical manufacturing, maintaining sterility is critical, particularly during terminal sterilization processes. An aseptic…

Unplanned Line Stoppage post-sterile filtration: facility, people, process root cause mapping

Root Cause Analysis of Unplanned Line Stoppage After Sterile Filtration The pharmaceutical industry often faces challenges that can result in unplanned line stoppages during critical processes such as sterile filtration.…

Air Entrapment during inspection preparation: GMP investigation and CAPA strategy

Addressing Air Entrapment Issues during Inspection Preparation in Pharmaceutical Manufacturing Air entrapment during inspection preparation can pose significant challenges in pharmaceutical manufacturing, particularly in the production of topical and dermatological…

Sterility Test Failure during aseptic filling: data integrity checks for lab and shop floor

Sterility Testing Failures during Aseptic Filling: Strategies for Data Integrity Checks Sterility test failures during aseptic filling present a significant challenge for pharmaceutical manufacturers, with implications that can ripple through…

Bioburden Spike Pre-Filtration during hold-time study: CAPA package with evidence and effectiveness checks

Addressing Bioburden Spikes During Pre-Filtration Hold-Time Studies Bioburden spikes during pre-filtration hold-time studies can pose significant risks to the sterility and quality of parenteral drug products. These incidents may lead…

Texture Variability in ointment filling: mixing and sampling controls for QA review

Addressing Texture Variability in Ointment Filling: A Comprehensive Investigation Approach Texture variability in ointment filling can significantly impact product quality and patient experience. Such variability can lead to deviations, Out…

Crystallization In Syrup during bulk hold: how QA should write CAPA for inspectors

Understanding Crystallization in Syrups During Bulk Hold: A Guide for Quality Assurance CAPA Crystallization in syrup formulations during the bulk holding process presents a critical challenge in pharmaceutical manufacturing, particularly…

Hold Time Bioburden Rise during EU/UK market supply: mixing, sampling, and hold-time controls

Addressing Bioburden Issues During Hold Time in EU/UK Pharmaceutical Supply Chains In the pharmaceutical manufacturing sector, maintaining product quality is paramount, especially for liquid oral dosage forms such as syrups…

Color Change in cream manufacturing: GMP investigation and CAPA strategy

Investigating Color Change in Cream Manufacturing: A Comprehensive GMP Approach Color changes in cream manufacturing can indicate significant quality issues, leading to Out of Specification (OOS) results and potential regulatory…

Foaming And Air Entrapment after temperature excursion: water system and sanitation checks

Investigating Foaming and Air Entrapment Issues Following Temperature Excursion in Pharmaceutical Water Systems Temperature excursions in pharmaceutical manufacturing can lead to significant process deviations, particularly in liquid oral dosage forms…